Synonyms: Careram® | Iremod | Kolbet® | T-614
iguratimod is an approved drug (China (2011), Japan (2012))
Compound class:
Synthetic organic
Comment: Iguratimod is a methanesulfonanilide disease-modifying anti-rheumatic drug [1,5-6]. Evidence from a mouse colitis model shows an anti-inflammatory effect of iguratimod, partly via regulation of Th17/Treg cells [4], that suggest iguratimod as a novel therapeutic for the treatment of IBD.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Bioactivity Comments |
Iguratimod inhibits the nuclear transcription factor NF-κB, but does not affect the NF-κB inhibitor IκBα [6]. It also inhibits cyclooxygenase-2, and suppresses IL-17 signalling [5], and inhibits the tautomerase activity of macrophage migration inhibitory factor (MIF) [2]. This latter action has shown synergy with glucocorticoids in vivo, in studies which suggest iguratimod to be suitable as a candidate for drug repurposing to MIF-relevant diseases [3], including multiple sclerosis. |
Selectivity at ligand targets | ||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|